The ThinPrep Difference
HPV Testing with the ThinPrep Pap Test: Out of the Vial
The ThinPrep Pap Test is approved by the U.S. Food and Drug Administration (FDA) as a platform for HPV DNA testing directly from the ThinPrep Pap Test collection vial using the QIAGEN Hybrid Capture® 2* system. A study conducted by the National Cancer Institute concluded that HPV testing is a viable method for determining which patients with borderline pap results are at highest risk for developing cancer. The ThinPrep Pap Test method is also approved for Chlamydia trachomatis (CT) and Neisseria Gonorrhea (NG) testing directly from the ThinPrep Pap Test collection vial using Roche Diagnostics Corporation's COBAS AMPLICOR™* automated system and Gen-Probe's APTIMA COMBO 2® * CT/NG assay.
The ThinPrep Pap Test is the preferred approach when liquid-based cytology is used.1-3
*Hybrid Capture® 2 (hc2) is a registered trademark of QIAGEN Group Corporation. COBAS AMPLICOR™ is a trademark of Roche Diagnostics Corporation. APTIMA COMBO 2® is a registered trademark of Gen-Probe Inc.
Next: cost effectiveness of the ThinPrep Pap Test
References
1. Richart R (moderator), Cox J, Twiggs L, Wilkinson E, Wright T. A sea change in diagnosing and managing HPV and cervical cancer - Part 1 (symposium). Contemporary Ob/Gyn. 2002;47:42-4,47-8,51-2,54,56.
2. Wright T, Cox J, Massad LS, Twiggs L, Wilkinson E. 2001 consensus guidelines for the management of women with cervical abnormalities. JAMA. 2002;287:2120-9.
3. Manos MM, et al. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-10. For additional information on ASC-US management, please see ASCCP "Algorithms from the Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities."
The Experts on
Pap Testing
See clinical guidelines on pap testing, HPV testing, and imaging technology.
Patient Educational Materials
Educate your patients about pap testing and HPV.